Navigation Links
Older patients with 1 type of heart failure may receive little or no benefit from drugs
Date:3/12/2009

LOS ANGELES (EMBARGOED UNTIL: 9 a.m. EST, March 12, 2009) People over 80 years of age suffering from a certain type of heart failure do not appear to benefit from most commonly prescribed heart medications, according to a study conducted at the Cedars-Sinai Heart Institute and published in the March 15 issue of The American Journal of Cardiology.

"The American population continues to live longer lives, often surviving with heart failure and other chronic conditions, but patients in this age range are typically excluded from medical research. Our review of 142 patient cases found that medications had little if any beneficial effect on five-year survival or rehospitalization for heart problems among elderly patients who have heart failure but an ejection fraction of at least 50 percent," said Cedars-Sinai Heart Institute cardiologist Ernst R. Schwarz, M.D., Ph.D., the article's senior author.

Ejection fraction is a measure of the pumping capacity of the left ventricle, the main pumping chamber of the heart. Heart failure with "preserved ejection fraction" a prevalent condition in the geriatric population is characterized by the heart contracting well but failing to relax, which prevents the chamber from properly filling with blood. Often termed "diastolic heart failure," this type of heart failure is more prominent than other forms among the elderly, women, and obese people but, like other types of heart failure, it typically has a poor prognosis and a very high mortality rate.

The authors noted that while the study found no proven benefit for drug therapy in this group of patients, cardiovascular medications are often prescribed, at both financial and physiologic cost. They urge special caution in prescribing digoxin and diuretics medications that are often used to treat congestive heart failure and other cardiac conditions because the study showed a trend toward increased mortality.

The average age of patients in this study was 87 years at the time of initial hospitalization with heart failure; 31 percent of the subjects were men. Sixty-nine percent of the patients died during the five-year follow-up, and none of the drug therapies statins, angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers, beta blockers, diuretics, calcium channel blockers, nitrates, and digoxin appeared to make a significant difference in which patients survived and which did not.

"The risk of adverse drug effects in the geriatric population is high. Because older patients may be taking multiple medications for a variety of medical conditions, and because drugs may affect older people differently than they do younger people, it is important for physicians to prescribe heart medications judiciously and account for a different and often more severe side effect spectrum" said Schwarz, professor of medicine at Cedars-Sinai Medical Center, medical director of the Cardiac Support Program and co-director of the Heart Transplant Program at the Cedars-Sinai Heart Institute. The study points out that more research is needed to evaluate the effects of therapies among the very elderly patients with heart failure.


'/>"/>

Contact: Sally Stewart
sally.stewart@cshs.org
310-248-6566
Cedars-Sinai Medical Center
Source:Eurekalert

Related medicine news :

1. Ability to cope with stress can increase good cholesterol in older white men, study finds
2. Many Older Americans Have Active Sex Lives
3. Good Cholesterol Wont Help Heavy-Drinking Older Men
4. Manor Care, Inc. Announces Record Date for Special Stockholder Meeting
5. Arrow International Urges Shareholders To Vote for Approval of the $45.50 Teleflex Inc. Merger and for the Current Board of Directors
6. Frequent alcohol consumption increases cancer risk in older women
7. Zimmer Holdings Offer and ORTHOsoft Directors Circular Mailed to Shareholders
8. ISS and Glass Lewis Recommend Cholestech Stockholders Vote FOR Merger
9. Glass Lewis Recommends Arrow Shareholders Vote on the White Proxy Card for Merger With Teleflex and for Current Board of Directors at Arrow Annual Meeting
10. Drug-free treatments offer hope for older people in pain
11. United Medicorp, Inc.s Shareholders Approve All Proposals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... ... 2017 , ... Dr. Angela Cotey, a noted general dentist in Mt. Horeb, ... with or without a referral. Dr. Cotey knows that interceptive orthodontics in ... When patients receive early treatment, they may achieve straight teeth with less treatment in ...
(Date:3/29/2017)... ... March 29, 2017 , ... Curio Wellness , a premium medical ... of the company’s executive management team with prominent executives from both inside and outside ... Chief Operating Officer, Ted Dumbauld , who has more than twenty years of ...
(Date:3/29/2017)... ... , ... Immunotherapy has emerged as one of the most promising options for ... the next revolution in our fight against this complex disease. One of the most ... inhibitors such as PD-1 and PD-L1 inhibitors. , While a few single analyte immunohistochemistry ...
(Date:3/29/2017)... , ... March 29, 2017 , ... The Wharton School ... and Julie Taffet Moelis, W’81, have made a $10 million gift to establish the ... opportunity that will provide a pathway to a Wharton MBA for highly-qualified Penn undergraduates ...
(Date:3/28/2017)... Los Angeles, CA (PRWEB) , ... March 28, 2017 , ... ... “wake-up call” asking the American public to take the Diabetes Risk Test to find ... the event, the Los Angeles World Airports will light up the evening sky by ...
Breaking Medicine News(10 mins):
(Date:3/29/2017)... 29, 2017   Dynatronics Corporation (NASDAQ: ... of Cynthia L. McHenry (Cyndi) as ... for leading Dynatronics manufacturing, distribution, and purchasing operations ... Dynatronics, CEO Kelvyn H. Cullimore, Jr. ... search process conducted by the company as it ...
(Date:3/29/2017)... 29, 2017 On March 28, the U.S. Food and ... with relapsing forms of multiple sclerosis (MS) and primary ... approved by the FDA for PPMS. Ocrevus is an ... "Multiple sclerosis can have a profound impact ... M.D., director of the Division of Neurology Products in ...
(Date:3/29/2017)... , March 29, 2017 /PRNewswire/ - Medicure Inc. ... release financial results for the year ended December ... 26, 2017. The results are being released later ... financial statements will include the operations and balances ... 1, 2016.  This release and filing date meets ...
Breaking Medicine Technology: